Evaluate the Safety and PK of Proellex® in Female Patients With Impaired Hepatic Function and Healthy Adults

Inclusion Criteria

• •Speak, read, and understand English or Spanish and is willing and able to provide written informed consent on an IRB-approved form prior to the initiation of any study procedures;
• •Female, between the ages of 18 and 48 years with Body Mass Index (BMI) between 18 and 39, inclusive, are preferred; however, subjects up to 62 years old, inclusive, may participate;
• •Subjects with moderate hepatic insufficiency must meet the Class B level of the Child-Pugh criteria;
• •Subjects must have evidence of stable hepatic impairment;
• •If on medications for treatment of the complications of liver disease, and other concomitant chronic illnesses, subjects must have been taking the medications at a stable dose for at least 10 days prior to the first dosing date and are then to be continued at the same dose for the duration of the study;
• •Non-smokers are preferred, but light to moderate smoking will be allowed (no more than 10 cigarettes/day)
• •Subject is willing to remain in the clinic for the screening visit and for two treatment visits (approximately 3 days for each treatment visit);